NervGen Pharma Corp.
NGEN.V
TSX
| Weiss Ratings | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.07 | |||
| Price History | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 13.36% | |||
| 30-Day Total Return | 7.61% | |||
| 60-Day Total Return | -3.57% | |||
| 90-Day Total Return | 6.45% | |||
| Year to Date Total Return | -10.54% | |||
| 1-Year Total Return | 37.50% | |||
| 2-Year Total Return | 58.82% | |||
| 3-Year Total Return | 38.79% | |||
| 5-Year Total Return | 143.44% | |||
| 52-Week High % Change | -13.10% | |||
| 52-Week Low % Change | 76.97% | |||
| Price | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.36 | |||
| 52-Week Low Price | $1.65 | |||
| 52-Week Low Price (Date) | Jun 05, 2024 | |||
| 52-Week High Price (Date) | Jan 03, 2025 | |||
| Valuation | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 144.89M | |||
| Enterprise Value | 132.83M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.27 | |||
| Earnings Per Share Growth | 9.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 30.17 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.97 | |||
| Enterprise Value/EBITDA (TTM) | -7.88 | |||
| Enterprise Value/EBIT | -7.86 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 70.07M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 778 731 1711 | |||
| Address | 112-970 Burrard Street Vancouver, BC V6Z 2R4 | |||
| Website | www.nervgen.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -73.56% | |||
| Return on Equity | -- | |||
| Income Statement | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -16.86M | |||
| EBIT (TTM) | -16.90M | |||
| Net Income (TTM) | -17.62M | |||
| Net Income Avl. to Common (TTM) | -17.62M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -19.44% | |||
| EPS Diluted (TTM) | -0.27 | |||
| EPS Diluted Growth (Q YOY) | -1.30% | |||
| Balance Sheet | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 15.55M | |||
| Cash Per Share (Q) | $0.22 | |||
| Total Current Assets (Q) | 16.24M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 6.79M | |||
| Current Ratio (Q) | 1.657 | |||
| Book Value Per Share (Q) | $0.10 | |||
| Total Assets (Q) | 16.62M | |||
| Total Current Liabilities (Q) | 9.81M | |||
| Total Debt (Q) | 95.50K | |||
| Total Liabilities (Q) | 9.83M | |||
| Total Common Equity (Q) | 6.79M | |||
| Cash Flow | NGEN.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 24.60K | |||
| Cash from Financing (TTM) | 16.66M | |||
| Net Change in Cash (TTM) | 4.72M | |||
| Levered Free Cash Flow (TTM) | -4.98M | |||
| Cash from Operations (TTM) | -11.95M | |||
